Oral JAK3 (PF-06651600) and TYK2/JAK1 (PF-06700841) inhibitors were shown to be efficacious and well tolerated in patients with moderate to severe (50% scalp hair loss) alopecia areata (AA). A substudy of this Phase 2 trial (PF-06651600, n¼18; PF-06700841, n¼16; placebo, n¼12) evaluated changes in lesional scalp biomarkers after 12 and 24 weeks of treatment using microarrays, qPCR, and immunohistochemistry. A total of 2264 genes were significantly up-or downregulated after 12 or 24 weeks of treatment across all patients and treatment groups (fold change >1.5; p<0.05). Significant gene-level changes from baseline in lesional transcriptomic profiles of 62% and 115% (12 weeks) and 162% and 104% (24 weeks) were obtained in the PF-06651600 and PF-06700841 groups, respectively, which differed significantly from those in the placebo group (week 12, 18%; week 24, 6%). With both treatments, patient-level T-cell activation, Th1, Th2, and IL12/23 pathways were significantly downregulated (p<0.05 at weeks 12 and/or 24) and hair keratins (KRT35, 40, 75, 83, 85, 86, KRTAP1) were significantly upregulated (p<0.05 at weeks 12 and/or 24). Most of these changes were significantly correlated (p<0.05) with clinical (Severity of Alopecia Tool score) improvements from baseline. No significant changes were seen with placebo. Greater improvements in clinical and transcriptomic parameters correlated with a shorter AA duration (<3.5 years). Overall, clinical improvements in patients with AA treated with PF-06651600 and PF-06700841 were associated with downregulation of Th1, Th2, and IL-12/23 immune responses and upregulation of hair keratins, with greater responses in patients with shorter disease duration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.